Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.31 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Fluoride SCHEMBL1500218 | 1.00 | CA2 (0.32) | CA2MEN1ALDH1A1HSP90AA1CYP2C9 | |
| SCHEMBL905746 | 0.97 | CA2 (0.33) | CA2MEN1ALDH1A1HSP90AA1CYP2C9 | |
| SCHEMBL7153290 | 0.80 | PTGS1 (0.31) | CYP2C19 | |
| SCHEMBL27395541 | 0.77 | — | — | |
| SCHEMBL13946196 | 0.74 | — | — | |
| SCHEMBL27592430 | 0.72 | USP2 (0.35) | ALDH1A1 | |
| SCHEMBL1167763 | 0.72 | CA2 (0.30) | CA2 | |
| Fluoride SCHEMBL4324376 | 0.72 | NR1I2 (0.32) | — | |
| Fluoride SCHEMBL9950038 | 0.72 | NR1I2 (0.32) | — | |
| SCHEMBL5679520 | 0.70 | TP53 (0.30) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11746099-B2 | Method for producing optically active pyrrolidine compounds | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2023-09-05 | — | — | US | disclosed |
| EP-3578545-B1 | METHOD FOR PRODUCING OPTICALLY ACTIVE PYRROLIDINE COMPOUNDS | MITSUBISHI TANABE PHARMA CORP (JP) | 2023-07-26 | — | — | EP | disclosed |
| US-20220119364-A2 | METHOD FOR PRODUCING OPTICALLY ACTIVE PYRROLIDINE COMPOUNDS | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2022-04-21 | — | — | US | disclosed |
| US-20210300896-A1 | METHOD FOR PRODUCING OPTICALLY ACTIVE PYRROLIDINE COMPOUNDS | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2021-09-30 | — | — | US | disclosed |
| US-6146547-A | USEFUL AS COMPONENT OF FERROELECTRIC LIQUID CRYSTAL FORMULATIONS | CHISSO CORPORATION (JP) | 2000-11-14 | — | — | US | disclosed |
| EP-0278665-B1 | 2-Substituted-alkyl ether and liquid crystal composition | CHISSO CORP (JP) | 1994-09-21 | — | — | EP | disclosed |
| US-5120468-A | Optical active mixture exhibiting ferroelectricity | CHISSO CORPORATION (JP) | 1992-06-09 | — | — | US | disclosed |
| EP-0278665-A2 | 2-Substituted-alkyl ether and liquid crystal composition | Chisso Corporation (JP) | 1988-08-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11746099-B2 | Method for producing optically active pyrrolidine compounds | ME1, ALDH18A1, ALAD | CA2 358/4885MEN1 2176/4885ALDH1A1 110/4885 |
| US-20220119364-A2 | METHOD FOR PRODUCING OPTICALLY ACTIVE PYRROLIDINE COMPOUNDS | ME1, ALDH18A1, ALAD | CA2 369/4885MEN1 2231/4885ALDH1A1 112/4885 |
| US-20210300896-A1 | METHOD FOR PRODUCING OPTICALLY ACTIVE PYRROLIDINE COMPOUNDS | ME1, ALDH18A1, ALAD | CA2 369/4885MEN1 2231/4885ALDH1A1 112/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.